By continuing to use our site, you consent to the processing of cookies, user data (location information, type and version of the OS, the type and version of the browser, the type of device and the resolution of its screen, the source of where the user came from, from which site or for what advertisement, language OS and Browser, which pages are opened and to which buttons the user presses, ip-address) for the purpose of site functioning, retargeting and statistical surveys and reviews. If you do not want your data to be processed, please leave the site.

The Voice of People With Breast Cancer


& Resources


Subsequent Entry Biologics: Why these drugs should matter to you 

This free one hour webinar took place on February 17, 2015 and was open to anyone interested in gaining a better understanding of Subsequent Entry Biologics and how these drugs impact breast cancer treatment.

SEBs, also known as biosimilars, are biologic drugs similar to an innovator product previously approved by Health Canada. Because the new drug is a biologic, it is not exactly the same as the drug it may replace.

We anticipate that SEB’s will be introduced into breast cancer treatment in about five years when Herceptin comes off patent.

SEBs have been part of the arthritis community for a number of years now. In the webinar, arthritis advocate Cheryl Koehn will explain how the arthritis community has dealt with SEBs and what we can expect once SEBs for breast cancer enter the marketplace.

Learning Outcomes:

  • What are Subsequent Entry Biologics, or SEBs?
  • Why should you care about SEBs?
  • What breast cancer specific biologics will be affected?
  • How did the arthritis community prepare for their arrival into the marketplace?
  • What can you do to stay abreast of SEB developments in breast cancer?



Your path to accessing financial resources

Quick Find

Our Stories


See our calendar